Genetic screening of an at-risk population for Hereditary TransthyRetin-related AMyloidosis and longitudinal monitoring of TTR positive subjects - TRAMmoniTTR

Centogene AG Rostock0 个研究点目标入组 5,000 人开始时间: 2019年3月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Informed consent is obtained from the participant
•The participant has no diagnosis of alcoholism according to international guidelines
•The participant has not undergone chemotherapy for any carcinoma
•The participant is at risk for hATTR due to two or more the factors listed below:
•- cardiomyopathy or polyneuropathy with no obvious etiology
•- atypical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Motor Neuron Disease (MND)
•- autonomic dysfunction
•- hypertrophic cardiomyopathy or heart failure with preserved ejection fraction Left Ventricular Hypertrophy (LVH)
•- bilateral carpal tunnel syndrome
•- spinal stenosis or spinal radiculopathy
•- gait disorders
•- ocular changes involving vitreous opacities
•- unexplained weight loss >5kg
•- renal abnormalities
•- family history of hATTR
•- based on imaging or biopsy suspected for the wild type TTR (ATTR) and not genetically tested for hATTR
•The participant is diagnosed with hATTR
•The participant is a 1st or 2nd degree relative of the TTR positive subject

•Informed consent is not obtained from the participant
•The participant is younger than 18 years of age
•The participant has a diagnosis of alcoholism according to International guidelines
•The participant has undergone chemotherapy for any carcinoma
•The participant is not at risk for hATTR

发起方

Centogene AG Rostock